ArticleFrontiers in pharmacology2021
Polypharmacy to Mitigate Acute and Delayed Radiation Syndromes.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026Review
- Molecular Lung Imaging Following Exposure to Radiation Predicts Long-Term Survival in Rats.International journal of molecular sciences · 2026Article
- Serum Metabolomic Signatures in Nonhuman Primates Treated with a Countermeasure and Exposed to Partial- or Total-Body Radiation.Metabolites · 2025Article
- Nicotinamide riboside alleviates ionizing radiation-induced intestinal senescence by alleviating oxidative damage and regulating intestinal metabolism.Journal of advanced research · 2025Article
- Modulation of β-Catenin promotes WNT expression in macrophages and mitigates intestinal injury.Cell communication and signaling : CCS · 2025Article
- IEPA, a novel radiation countermeasure, alleviates acute radiation syndrome in rodents.International journal of radiation biology · 2025Article
- Time- and sex-dependent delayed effects of acute radiation exposure manifest via miRNA dysregulation.iScience · 2024Article
- Sex differences in radiation research.International journal of radiation biology · 2024Article
- Delayed effects of radiation exposure in a C57L/J mouse model of partial body irradiation with ~2.5% bone marrow shielding.Frontiers in public health · 2024Article
- Radiation-induced multi-organ injury.International journal of radiation biology · 2024Article
- Considerations of Medical Preparedness to Assess and Treat Various Populations During a Radiation Public Health Emergency.Radiation research · 2023Review
- The delayed effects of acute radiation exposure (DEARE): characteristics, mechanisms, animal models, and promising medical countermeasures.International journal of radiation biology · 2023Review
- Delayed renal injury in survivors of hematologic acute radiation syndrome.International journal of radiation biology · 2023Article
- Animal Care in Radiation Medical Countermeasures Studies.Radiation research · 2022Article
- Mitigation of Multi-Organ Radiation Injury with ACE2 Agonist Diminazene Aceturate.Radiation research · 2022Article
- Vascular regression in the kidney: changes in 3D vessel structure with time post-irradiation.Biomedical optics express · 2022Article
- Pharmacologic ACE-Inhibition Mitigates Radiation-Induced Pneumonitis by Suppressing ACE-Expressing Lung Myeloid Cells.International journal of radiation oncology, biology, physics · 2022Article
- Meeting Report: A Poly-Pharmacy Approach to Mitigate Acute Radiation Syndrome.Radiation research · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
There is a need for countermeasures to mitigate lethal acute radiation syndrome (ARS) and delayed effects of acute radiation exposure (DEARE). In WAG/RijCmcr rats, ARS occurs by 30-days following total body irradiation (TBI), and manifests as potentially lethal gastrointestinal (GI) and hematopoietic (H-ARS) toxicities after >12.5 and >7 Gy, respectively. DEARE, which includes potentially lethal lung and kidney injuries, is observed after partial body irradiation >12.5 Gy, with one hind limb shielded (leg-out PBI). The goal of this study is to enhance survival from ARS and DEARE by polypharmacy, since no monotherapy has demonstrated efficacy to mitigate both sets of injuries. For mitigation of ARS following 7.5 Gy TBI, a combination of three hematopoietic growth factors (polyethylene glycol (PEG) human granulocyte colony-stimulating factor (hG-CSF), PEG murine granulocyte-macrophage-CSF (mGM-CSF), and PEG human Interleukin (hIL)-11), which have shown survival efficacy in murine models of H-ARS were tested. This triple combination (TC) enhanced survival by 30-days from ∼25% to >60%. The TC was then combined with proven medical countermeasures for GI-ARS and DEARE, namely enrofloxacin, saline and the angiotensin converting enzyme inhibitor, lisinopril. This combination of ARS and DEARE mitigators improved survival from GI-ARS, H-ARS, and DEARE after 7.5 Gy TBI or 13 Gy PBI. Circulating blood cell recovery as well as lung and kidney function were also improved by TC + lisinopril. Taken together these results demonstrate an efficacious polypharmacy to mitigate radiation-induced ARS and DEARE in rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.